Seagen To Highlight Overall Survival Data For PADCEV And TIVDAK During Presidential Symposium At ESMO Congress 2023
Portfolio Pulse from Benzinga Newsdesk
Seagen Inc. (NASDAQ:SGEN) will present detailed results from two pivotal Phase 3 studies at the ESMO Congress 2023. The studies focus on PADCEV (EV-302) for bladder cancer and TIVDAK (innovaTV 301) for cervical cancer. Both studies met their primary endpoints of overall survival and progression-free survival. The results will be used for global submissions and as confirmatory trials for U.S. accelerated approval. Seagen is also sharing early clinical data from a Phase 1 study of SGN-B7H4V, a wholly owned vedotin ADC directed to B7-H4.
October 16, 2023 | 12:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Seagen's upcoming presentation of Phase 3 results for PADCEV and TIVDAK at ESMO Congress 2023 could potentially boost investor confidence. The positive results could also expedite regulatory approval processes.
The positive results from the Phase 3 studies of PADCEV and TIVDAK indicate that these drugs are effective in treating bladder and cervical cancer respectively. This could potentially lead to accelerated regulatory approval, which would allow Seagen to bring these drugs to market sooner. This could boost the company's revenues and profitability, which would likely be viewed positively by investors.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100